CRSP (CRISPR Therapeutics AG) FFO


CRSP CRISPR Therapeutics AG CRSP
41 GF Score
Price $53.55
GF Value $2.42
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is CRISPR Therapeutics AG FFO?

FFO (Funds from operations) only applies to REITs.

CRSP
41GF Score
CRISPR Therapeutics AG CRSP
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is CRISPR Therapeutics AG (CRSP) Overvalued in 2026?

Based on GuruFocus' analysis, CRISPR Therapeutics AG stock appears to be overvalued. The current stock price of $53.55 is trading 2112.8% above its estimated GF Value™ of $2.42. GuruFocus considers CRISPR Therapeutics AG to be Significantly Overvalued.

Key valuation signals for CRSP:

  • FFO:
  • GF Value™: $2.42 vs. price of $53.55 (2112.8% above fair value)
  • GF Score™: 41/100 with 4 warning signs

No single metric tells the full story. See the CRSP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CRISPR Therapeutics AG Business Description

Address Baarerstrasse 14, Zug, CHE, 6300
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
41GF Score

Get the complete analysis for CRSP

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$53.55
Price
$2.42
GF Value